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Hyperglycemia-induced diaphragm weakness is
mediated by oxidative stress
Leigh A Callahan*† and Gerald S Supinski†

Abstract
Introduction: A major consequence of ICU-acquired weakness (ICUAW) is diaphragm weakness, which prolongs
the duration of mechanical ventilation. Hyperglycemia (HG) is a risk factor for ICUAW. However, the mechanisms
underlying HG-induced respiratory muscle weakness are not known. Excessive reactive oxygen species (ROS) injure
multiple tissues during HG, but only one study suggests that excessive ROS generation may be linked to HG-induced
diaphragm weakness. We hypothesized that HG-induced diaphragm dysfunction is mediated by excessive superoxide
generation and that administration of a specific superoxide scavenger, polyethylene glycol superoxide dismutase
(PEG-SOD), would ameliorate these effects.
Methods: HG was induced in rats using streptozotocin (60 mg/kg intravenously) and the following groups
assessed at two weeks: controls, HG, HG + PEG-SOD (2,000U/kg/d intraperitoneally for seven days), and HG +
denatured (dn)PEG-SOD (2000U/kg/d intraperitoneally for seven days). PEG-SOD and dnPEG-SOD were administered on
day 8, we measured diaphragm specific force generation in muscle strips, force-pCa relationships in single
permeabilized fibers, contractile protein content and indices of oxidative stress.
Results: HG reduced diaphragm specific force generation, altered single fiber force-pCa relationships, depleted
troponin T, and increased oxidative stress. PEG-SOD prevented HG-induced reductions in diaphragm specific force
generation (for example 80 Hz force was 26.4 ± 0.9, 15.4 ± 0.9, 24.0 ± 1.5 and 14.9 ± 0.9 N/cm2 for control, HG, HG +
PEG-SOD, and HG + dnPEG-SOD groups, respectively, P <0.001). PEG-SOD also restored HG-induced reductions in
diaphragm single fiber force generation (for example, Fmax was 182.9 ± 1.8, 85.7 ± 2.0, 148.6 ± 2.4 and 90.9 ± 1.5 kPa in
control, HG, HG + PEG-SOD, and HG + dnPEG-SOD groups, respectively, P <0.001). HG-induced troponin T depletion,
protein nitrotyrosine formation, and carbonyl modifications were largely prevented by PEG-SOD.
Conclusions: HG-induced reductions in diaphragm force generation occur largely at the level
of the contractile proteins, are associated with depletion of troponin T and increased indices of oxidative stress, findings
not previously reported. Importantly, administration of PEG-SOD largely ablated these derangements, indicating that
superoxide generation plays a major role in hyperglycemia-induced diaphragm dysfunction. This new mechanistic
information could explain how HG alters diaphragm function during critical illness.

Introduction
A major consequence of ICU acquired skeletal muscle
weakness (ICUAW) is respiratory muscle dysfunction
which leads to prolonged duration of mechanical ventilation [1]. Importantly, a number of recent studies indicate
that critically ill mechanically ventilated patients have
severe respiratory muscle weakness, with diaphragm force
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generation averaging only 23% of the level observed in
healthy individuals [2-5]. In addition, clinical studies
have identified a number of factors that are thought to
contribute to ICU acquired diaphragm weakness including
mechanical ventilation induced respiratory muscle inactivity, sepsis/infections, use of corticosteroids and hyperglycemia [6-8].
Several recent reports indicate that hyperglycemia detrimentally affects respiratory muscle performance in ICU
patients [9-13]. Specifically, Van den Berghe et al. found
that intensive insulin therapy (that is, administration of
insulin to maintain blood glucose in the 80 to 110 mg/dl
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range) in ICU patients markedly reduced the time required
to wean patients from mechanical ventilation, shortened
ICU stay, and was associated with decreased incidence
of ICUAW [9,13]. In later work, this group showed that
electromyographic abnormalities consistent with the diagnosis of ICUAW were prevented with intensive control
of blood glucose levels [10,12]. In addition, more strict
control of glucose reduced the duration of mechanical
ventilation [10]. Moreover, numerous clinical studies in
patients with a variety of diagnoses have now established
that the presence of acute hyperglycemia is associated
with poor outcomes, including increased mortality during
critical illness [14,15].
The strongest evidence that hyperglycemia is a risk
factor for acquired respiratory muscle weakness in ICU
patients is borne out by these clinical observations [16].
However, the cellular mechanisms by which acute hyperglycemia induces respiratory muscle weakness are not
known. On the other hand, previous studies indicate that
hyperglycemia induces excessive generation of superoxide
and other reactive oxygen species (ROS) in several tissues,
including the vascular endothelium, the retina and kidneys
[17-19] and that excessive ROS generation mediates the
long term complications of diabetes in these organs. In
addition, excessive ROS formation has been shown to
mediate the development of skeletal muscle contractile
dysfunction in several diseases, including sepsis, heart
failure and inactivity induced muscle atrophy [20-26].
Only one previous animal study has provided a potential
link between hyperglycemia induced diaphragm weakness
and excessive ROS generation. In this study, Hida et al.
[27] found that after two weeks of streptozotocin (STZ)
induced hyperglycemia, diaphragm specific force generation was significantly reduced and that administration
of a non-specific antioxidant, N-acetyl cysteine (NAC)
restored these reductions. In their conclusion, these
authors speculated that NAC may have exerted its
effects either by scavenging free radicals or by inhibiting
tumor necrosis factor [27]. However, this study did not
determine how hyperglycemia altered diaphragm contractility or assess if hyperglycemia actually induced oxidative
stress in the diaphragm.
Given the recent recognition that hyperglycemia is a
major clinical risk factor for ICU acquired diaphragm
weakness, that excessive ROS generation plays a role in
hyperglycemia-induced organ injury in multiple tissues
(and, possibly, the diaphragm based on the single study
cited above) and that excessive ROS generation has been
implicated in diaphragm weakness in other conditions,
we postulated that hyperglycemia may induce excessive
superoxide generation in the diaphragm and may be
responsible for the development of hyperglycemia-induced
reductions in diaphragm contractility. Therefore, the purpose of the present study was to test this hypothesis using
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an animal model of hyperglycemia (that is, STZ-induced
hyperglycemia) and to determine further the specific role
of oxidative stress in modulating diaphragm dysfunction
during hyperglycemia. We compared diaphragm force
generation in intact diaphragm muscle strips, single fiber
force-pCa relationships, levels of key contractile proteins
and indices of ROS-mediated protein modifications in
four groups of rats including sham treated euglycemic
controls, hyperglycemic animals, hyperglycemic animals
given a specific superoxide scavenger, polyethylene glycolsuperoxide dismutase (PEG-SOD) and hyperglycemic animals given enzymatically inactive, denatured PEG-SOD.
Data were analyzed to determine the subcellular targets
by which hyperglycemia reduces diaphragm force generating capacity and to determine if treatment with active
PEG-SOD, a specific scavenger of excessive superoxide
generation, would reverse hyperglycemia-induced alterations in the diaphragm.
We chose to focus on the diaphragm specifically because
respiratory muscle weakness in the ICU is a major clinical
problem [2,3], and diaphragm weakness in ICU patients
has been shown to result in poor outcomes, including
prolonged duration of mechanical ventilation, increased
incidence of patient transfers to long term ventilator
units and higher ICU mortality [2,3]. In addition, there
is strong clinical data showing that strict glucose control
reduces ICU acquired diaphragm weakness, shortening
duration of mechanical ventilation and ICU length of stay
in critically ill patients [9,10,16]. Finally, there is a paucity
of mechanistic information regarding the effects of hyperglycemia on the diaphragm.

Materials and Methods
All studies were approved by the University of Kentucky
Institutional Animal Care and Use Committee (Animal
assurance number A3336-01). Care and handling of animals was in accordance with the guidelines of the National
Institutes of Health Office of Lab Animal Welfare.
Experimental models and protocols

Experiments were performed using adult male Sprague
Dawley rats weighing between 250 and 350 gm. Animals
had unrestrained access to food and water throughout
the study. To prevent dehydration, animals were housed
individually and supplied with two water sources. Animals
were monitored throughout experiments by members of
the University of Kentucky Division of Laboratory Animal
Resources as well as research personnel.
In pilot studies, we assessed diaphragm contractile function at several time points and noted consistent reductions
in diaphragm contractility at two weeks. As a result, we
chose to perform studies at this time point. This time
point is relevant to ICU acquired diaphragm weakness
which is most often clinically recognized when patients
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are unable to be weaned, which usually occurs after at
least seven days of mechanical ventilation [6,8].
Four groups of animals were studied, including: (1)
sham treated euglycemic controls, (2) streptozotocin
(STZ)-treated hyperglycemic animals, (3) STZ-treated
hyperglycemic animals given a superoxide scavenger
(PEG-SOD), and (4) STZ-treated hyperglycemic animals
given enzymatically inactive, denatured PEG-SOD. Hyperglycemia was induced by a single tail vein injection of
STZ (60 mg/kg) (Sigma Chemicals, St Louis, MO, USA)
dissolved in citrate buffer (pH 4.5). Sham-treated controls
were injected via tail vein with an equivalent volume of
citrate buffer alone. Tail vein blood was used to assess
blood glucose levels on days 2 and 7 post injection of
STZ or buffer in all animals to document hyperglycemia
(glucose >300 mg/dl) in STZ-treated animals and euglycemia in controls. Measurements were performed using
a commercially available glucometer (Precision Xtra,
Abbott, Alameda, CA, USA). At one week after the initial
injections of STZ or citrate buffer, animals were then
treated with intraperitoneal injections of either saline,
PEG-SOD (2,000 units/kg/day), or denatured PEG-SOD
(heat denatured 2,000 units/kg/day) for a total of seven
days. On the day of sacrifice (two weeks after initial
injections), a final blood glucose determination was made
prior to administration of anesthetics, and animals were
subsequently deeply anesthetized (pentobarbital 150 mg/
kg injected intraperitoneally) and diaphragms harvested.
A portion of the left costal diaphragm was used immediately to assess force frequency relationships, a second
section was removed for determination of single fiber
force-pCa relationships, and a third section was frozen
and stored (at -80°C) for biochemical assessments of
contractile protein levels and ROS-mediated protein
modifications.
Measurement of diaphragm force-frequency relationships

Diaphragm specific force generation was assessed as previously reported [28-30]. Intact diaphragm strips were
dissected from the left costal diaphragm and mounted
vertically in water-jacketed organ baths (Radnoti, Monrovia,
CA, USA) containing Krebs-Henseleit solution (25°C,
curare 50 mg/L, pH 7.40, NaCl 135 mM, KCl 5 mM,
dextrose 11.1 mM, CaCl2 2.5 mM, MgSO4 1 mM, NaHCO3
14.9 mM, NaHPO4 1 mM, insulin 50 units/L, 95% O2/5%
CO2). The rib end of the strips was attached to the bottom
of the baths by silk ties, and the tendon end was tied to
a force transducer (Grass Technologies, West Warwick,
RI, USA). Platinum field electrodes were placed around
strips and connected to an amplifier (Biomedical Technology of America, Cleveland, Ohio, USA) attached to
a Grass S48 stimulator (Grass Technologies). After a
15 minute equilibrium period, muscle length was adjusted
to Lo (the length at which force generation was maximum),
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stimulation current was adjusted to supramaximal levels
and a force-frequency curve was constructed by stimulating
strips at 1, 10, 20, 50, and 80 Hz (train duration 800 msec)
with a 30 second rest period between adjacent stimulus
trains. Force was recorded with a Gould 2600 strip
chart recorder (Gould Instruments System, Cleveland,
Ohio, USA). After force measurements were completed,
transducers were calibrated with standard weights. Cross
sectional area was calculated as muscle strip weight
divided by muscle density (1.06) and muscle length;
diaphragm specific force generation was then calculated
as raw force divided by cross sectional area [31].
Assessment of force-pCa relationships in single
permeabilized diaphragm fibers

Force-pCa curves from single permeabilized diaphragm
fibers were determined as previously reported [24,32-34].
At the time of animal sacrifice, a portion of the diaphragm
was carefully removed from its intercostal insertions
and placed in a dissecting dish with a relaxing solution
containing (in mM): 1.0 Mg2+, 5.0 MgATP, 15 phosphocreatine, 140.0 potassium methanesulfonate, 50.0 imidazole
and 10.0 ethylene glycol tetraacetic acid (EGTA), with
pCa >8.5, pH 7.0 and an ionic strength of 200. Protease
inhibitors were added to the solution to protect the fibers
from the damaging effects of proteolysis and included the
following: 0.1 mM phenylmethysulfonyl fluoride, 0.1 mM
leupeptin, 1.0 mM benzamidine and 10 μM aprotinin.
The diaphragm was then divided into small strips and
stored at −20°C in the relaxing solution containing 50%
glycerol and protease inhibitors for later experimentation.
For the storage solution, CTP was used instead of ATP to
prevent phosphorylation of the myosin light chains. All
single-fiber assessments were completed within one week
of animal sacrifice.
On the day that single fiber characteristics were
assessed, diaphragm strips were removed from the
storage solution, placed in the relaxing solution and
equilibrated to room temperature. Bundles of approximately
10 fibers were gently separated from mid-costal diaphragm
strips by pulling on one end of the muscle with a pair of
fine-tipped forceps while the other end of the muscle was
stationary. Following this, fiber bundles were permeabilized
for 30 minutes in the relaxing solution containing 0.1%
Triton X-100, an ionic detergent that eliminates the membranes of the sarcolemma, sarcoplasmic reticulum and
mitochondria, leaving only the contractile proteins intact.
After incubation, bundles were removed from Triton
X-100, placed in the relaxing solution, and individual
fibers teased from the muscle bundles. Single fibers were
then mounted between an optoelectric force transducer
(Scientific Instruments, Heidelberg, Germany) and a movable arm by wrapping the ends of each fiber around
stainless steel clips. Fibers were adjusted to achieve a
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resting sarcomere length of 2.6 μm as indicated by its
helium-neon laser diffraction pattern. Length was constant throughout the protocol. The cross-sectional area
of each fiber was determined after adjustment of the
sarcomere length by measuring the diameter of the fiber
using a micrometer attached to the eyepiece of the microscope and area was subsequently calculated assuming a
cylindrical shape for the fiber.
Force versus pCa curves were then constructed for
fibers by immersing them in solutions of increasing
calcium concentrations and recording tension on a
strip recorder. Once peak tension was achieved in a
given pCa solution, fibers were rapidly switched to the
next solution by means of a spring-loaded Plexiglas
tray. The composition of all solutions for this study
was calculated by using a computer program (Borland
International, Scotts Valley, CA, USA) that takes into
account stability constants and stock solutions to produce
final solutions of the correct ionic strength and pCa
(12). Specifically, the pCa solutions contained (in mM):
1.0 Mg2+, 1.0 MgATP, 15 phosphocreatine, 110.0 potassium
methanesulfonate, 20.0 imidazole and 5.0 EGTA, with
pH 7.0, and ionic strength of 200. Addition of different
amounts of calcium yielded solutions of the desired pCa.
To establish the force versus pCa relationship, fibers were
submerged in a solution containing no added calcium
(pCa 8.5), followed by sequential exposure to 13 different
calcium solutions, namely pCa 6.0, 5.90, 5.80, 5.75, 5.70,
5.65, 5.60, 5.55, 5.50, 5.40, 5.30, 5.20 and 5.0. These solutions correspond to a range of calcium concentrations
of 10−6 to 10−5 M. Data were assessed using SigmaPlot
software (version 12.0, Jandel Scientific) to determine the
constant N related to the steepness of the force versus pCa
relationship (N is a measure of the extent of cooperativity
among the thin filaments) and the calcium concentration
required for half-maximal activation (Ca50) (K) values for
the force-pCa relationships from a best fit of the data to the
modified Hill equation: % maximum force = 100[Ca2+]N/
((K)N + [Ca2+]N). Averages and standard errors of the
mean for N values, Ca50, cross-sectional area, percentage
of Fmax and absolute force (normalized for cross-sectional
area) for individual diaphragm fibers were calculated for
fibers from the experimental groups.
Determination of diaphragm fiber type based on myosin
heavy chain isoforms

After determination of the force-pCa relationship, single
fibers were stored in sample buffer at −80°C and, subsequently, myosin heavy chain isoforms were determined
for each individual fiber using gel electrophoresis according to previously established methods [35]. Fibers were
classified based on their myosin heavy chain isoforms
as either Type IIA, Type IIX, Type IIX/IIB, Type IIB
or slow.
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Contractile protein level determination and assessment of
ROS mediated protein modifications by western blots

To determine if hyperglycemia induced alterations in
the content of the contractile proteins, western blots of
diaphragm homogenates were used to assess diaphragm
levels of actin, actinin, tropomyosin and troponin T. In
addition, since free radicals have been shown to modulate diaphragm dysfunction in a variety of animal models
[23-25], we also examined diaphragm muscle homogenates
for ROS-mediated protein modifications (nitrotyrosine
side group formation, protein carbonyl formation). For
these determinations, muscle samples were homogenized
in buffer (10 mM beta-glycerophosphate, 50 mM sodium
fluoride, 1 mM sodium, 20 mM 4-(2-hydroxyethyl)-1piperazine-ethanesulfonic acid (HEPES), 2 mM ethylenediaminetetraacetic acid (EDTA), 250 mM sodium
chloride, 2 microgram/ml leupeptin, 2 microgram/ml
aprotinin, 1 mM PMSF, 0.5 microgram/ml benzamidine,
and 1 mM dithiothreitol (DTT)) in a 1 gm/10 ml ratio,
centrifuged at 3,000 g for 10 minutes. Protein contents
of supernatants were assessed using the Bradford assay
(BioRad Laboratories, Hercules, CA, USA). Supernatants
were then diluted 1:1 with loading buffer (126 mM Tris–
HCl, 20% glycerol, 4% SDS, 1.0% 2-mercaptoethanol,
0.005% bromophenol blue, pH 6.8), boiled for five to
seven minutes and equal amounts of protein (2 to 10
micrograms) were loaded onto Tris-glycine polyacrylamide
gels. Proteins were separated by electrophoresis (Novex
Minicell II, Carlsbad, CA, USA), transferred to polyvinylidene fluoride (PDVF) membranes and incubated over night
at 4°C with primary antibodies to targeted proteins.
The following reagents were used: anti-actin, anti-actinin,
anti-tropomyosin and anti-troponin T (Sigma Aldrich, St.
Louis, MO, USA), and anti-nitrotyrosine (EMD Millipore
Corporation, Billerica, MA, USA). Protein carbonyl determinations were performed using the OxyBlot™ Protein
Oxidation Detection Kit (EMD Millipore Corporation)
following the manufacturer’s instructions. Following
incubation in the primary antibody, membranes were
washed and then subsequently incubated with horseradish
peroxidase (HRP)-conjugated secondary antibodies and
antibody binding detected using enhanced chemiluminescence (Western Lightning®-ECL, Perkin Elmer, Waltham,
MA, USA). Densitometry was performed using a Microtek
scanner (Carson, CA, USA) and UN-SCAN-IT software
(Silk Scientific, Orem, UT, USA). To verify equal loading
of lanes, blots were stripped and reprobed with antitubulin (Sigma Aldrich).
Statistical analysis

Analysis of variance (ANOVA) was employed to compare
variables (for example, force) across groups of animals
treated with different agents, with post-hoc testing (Tukey)
to determine differences between groups. A P <0.05 was
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taken as indicating statistical significance. Data are presented as ± 1 standard error of the mean (SEM).

showed that diaphragm specific force generation is reduced
after two weeks of hyperglycemia [27].

Results

Effects of hyperglycemia on diaphragm single fiber
force-pCa relationships

Animal characteristics

Control animals were euglycemic with glucose levels averaging 105 + 4 mg/dl (Table 1). At the time of sacrifice,
glucose levels were greater than 350 mg/dl in all three
STZ-treated groups. Importantly, administration of either
active PEG-SOD or denatured PEG-SOD had no effect
to lower glucose levels. Total body weight decreased
significantly in all hyperglycemia groups; the reduction
in body mass averaged 11 ± 2%, 13 ± 2% and 15 ± 1%
for hyperglycemia, hyperglycemia + PEG-SOD and hyperglycemia + denatured PEG-SOD groups, respectively
(P <0.001), when compared to control animals in which
total body weight increased by 13 ± 4%. Total costal
diaphragm weights also were significantly reduced in all
hyperglycemia groups when compared to controls (Table 1).
To further examine the effects of hyperglycemia and/or
administration of PEG-SOD on diaphragm atrophy, we
assessed the ratio of final diaphragm weights to final
animal weights, reasoning that reductions in this ratio
would be indicative of preferential diaphragm atrophy,
rather than generalized reductions in muscle mass
related to the global reduction in total body mass. As
shown in the figure in Additional file 1: Figure S1, there
was a trend for reductions in this ratio for the HG and
HG + denatured PEG-SOD treated groups compared to
the control group and HG + PEG-SOD groups, but these
comparisons were not statistically significant (P = 0.24).
Effects of hyperglycemia on diaphragm specific force
generation

The total force generated by a muscle is the product of
muscle size (that is, total cross sectional area) and the
force generating capacity per unit cross sectional area,
otherwise known as muscle specific force. As shown in
Figure 1, hyperglycemia resulted in a large reduction in
diaphragm specific force, decreasing levels of force generated across the entire range of stimulation frequencies
tested (P = .002 for 1 Hz, P <0.001 for all others). These
data confirm the previous report by Hida et al. which

To determine if the loss of diaphragm force generation
in response to hyperglycemia was the consequence of
alterations at the level of the contractile proteins, we
assessed the force-pCa relationship in 360 single permeabilized diaphragm fibers (Figure 2). We found that
hyperglycemia induced a large downshift in the diaphragm
contractile protein force-pCa relationship, reducing Fmax
from 182.9 ± 1.85 kPa to 85.7 ± 1.99 kPa (this is an index
of actin-myosin crossbridge formation) (P <0.001) and
decreasing the coefficient of cooperativity, N, from 5.98
to 5.17 (P = 0.015). Hyperglycemia did not, however,
alter the calcium sensitivity (pCa50) of the contractile
proteins (Table 2).
Effect of PEG-SOD on diaphragm specific force generation
in intact muscle strips

Administration of PEG-SOD largely reversed the effects
of hyperglycemia on diaphragm specific force generation,
restoring the force-frequency relationship measured on
intact diaphragm strips (Figure 3). Specifically, diaphragm
specific force generation (for example, 80 Hz force) was
26.4 ± 0.9, 15.4 ± 0.9, 24.0 ± 1.5 and 14.9 ± 0.9 N/cm2 for
control, two week hyperglycemia, two week hyperglycemia + PEG-SOD and two week hyperglycemia + denatured PEG-SOD groups, respectively (P <0.001). As shown
in Figure 3, PEG-SOD restored force generation at all
frequencies tested, similar to levels seen in control euglycemic animals.
Effect of PEG-SOD on diaphragm single fiber force-pCa
relationships

We also assessed single diaphragm fiber force-pCa relationships in hyperglycemic animals given PEG-SOD and
dnPEG-SOD. We found that PEG-SOD restored Fmax
and N values to control levels and shifted force-pCa
curves to levels similar to those for fibers from control,
euglycemic animals (Figure 4) (P <0.001 for Fmax and
P <0.001 for N values, respectively).

Table 1 Animal data
Experimental group

Initial animal
weight (grams)

Final animal
weight (grams)

Control

306 ± 13

342 ± 10

725 ± 61

105 ± 5

Hyperglycemia

295 ± 13

261 ± 9*

475 ± 31*

434 ± 18*

Hyperglycemia + PEG-SOD

325 ± 13

282 ± 9*

566 ± 26*

485 ± 15*

Hyperglycemia + denatured PEG-SOD

297 ± 9

253 ± 12*

453 ± 38*

489 ± 7*

*Significantly different when compared to control group (P <0.001).

Costal diaphragm
weight (mg)

Glucose
(mg/dL)
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Figure 1 Hyperglycemia alters diaphragm force-frequency curves. A) demonstrates representative force frequency curves (raw data from 1,
10, 20, 50 and 80 Hz stimulation frequencies) generated for intact diaphragm strips from a control animal treated with citrate buffer alone (left)
and from a hyperglycemic animal two weeks after the initial injection of STZ (right). B) demonstrates mean data ± SEM (n = 6) for control (black)
and two week hyperglycemic animals (red). As shown, hyperglycemia induced large reductions in the diaphragm specific force generation (force/
cross sectional area) at all stimulation frequencies when compared to control animals. (*P = .002 for 1 Hz, P ≤0.001 for all other stimulation
frequencies). SEM, standard error of the mean; STZ, streptozotocin.

Previous studies which have examined force-pCa relationships in the rat diaphragm have reported fiber type
specific changes in contractile protein characteristics
[35,36] as well as fiber type specific atrophy in a variety
of animal models (chronic obstructive pulmonary disease
(COPD), chronic corticosteroid treatment, cervical spinal
cord injury induced inactivity and mechanical ventilation)

[37]. To determine if hyperglycemia induced alterations
in single fiber force-pCa relationships were fiber-type
specific, we analyzed single fiber maximal force generation, pCa 50, N values (obtained from the Hill equation),
and fiber cross sectional area for Type IIA, IIX, IIX/IIB,
IIB and slow fibers across the experimental groups (see
the table in Additional file 2: Table S1 for details of this

Diaphragm Single Fiber Force (% Fmax)
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Control
Hyperglycemia
100
80
60
40
20
0
6.5

6.0
5.5
5.0
2+
pCa (-log [Ca ])

Figure 2 Hyperglycemia alters the force-pCa relationship in single permeabilized diaphragm fibers. Average force-Ca curves were
constructed for single fibers from control (black) and two week hyperglycemic animals (red) using the Hill equation (15 fibers from each of
six animals per condition for a total of 90 fibers per group). Symbols and error bars represent the mean ± SEM of the data points obtained for
each individual fiber. Force (Fmax) is the absolute force generation per cross sectional area of each individual fiber normalized to the percentage of
the control fibers. pCa represents the (−log [Ca 2+]) indicating that the calcium content in the solution increases along the X-axis. As shown,
two weeks of hyperglycemia significantly alters the force-pCa relationship in single permeabilized diaphragm fibers, indicating that most of
the hyperglycemia-induced diaphragm force reductions are due to alterations at the level of the contractile proteins (P <0.001 for force in
fibers from hyperglycemic groups compared to control fibers at all pCa values greater than 6.0). SEM, standard error of the mean.

Table 2 Data from single permeabilized diaphragm fibers
Experimental group

Maximum force
(kPa)

N
value

pCa50

Control

182.9 ± 1.8

5.98 ± 0.19

5.81 ± 0.01

Hyperglycemia

85.7 ± 2.0*

5.17 ± 0.27*

5.69 ± 0.07

Hyperglycemia + PEG-SOD

148.6 ± 2.4*

5.76 ± 0.22

5.78 ± 0.01

Hyperglycemia + Denatured PEG-SOD

90.9 ± 1.5*

4.33 ± 0.18*

5.72 ± 0.01

Single fiber maximum force is reported as absolute force generation per fiber cross sectional area in kPa. N is the Hill coefficient and indicates thin filament
cooperativity. pCa50 is the calcium concentration at which half maximal activation occurs. Data are presented as the mean ± standard error of the mean (SEM)
and include all fiber types for each experimental group (n = 90/group). *Significantly different when compared to control group (P < 0.001).
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2

Diaphragm Specific Force (N/cm )

Control
Hyperglycemia
Hyperglycemia + PEG-SOD
Hyperglycemia + Denatured PEG-SOD
30

*

25
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*

*
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0
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Frequency (Hz)
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Figure 3 Polyethylene glycol superoxide dismutase (PEG-SOD) restores hyperglycemia-induced reductions in the diaphragm forcefrequency response. Data are shown for intact diaphragm strips from control (black), hyperglycemia (red), hyperglycemia + PEG-SOD (blue) and
hyperglycemia + denatured (heat inactivated) PEG-SOD groups (green) obtained at two weeks after administration of citrate buffer (controls) or
streptozotocin (hyperglycemia) (n = 6 animals/group). PEG-SOD and denatured PEG-SOD were administered intraperitoneally at Day 7 after the initial
injection for a total duration of seven days. Administration of PEG-SOD largely restored diaphragm force generation in hyperglycemic animals to that
of controls, whereas denatured PEG-SOD had no effect; recovery of diaphragm specific force with PEG-SOD was not due to normalization of glucose
levels. (P ≤0.001, *control and hyperglycemic + PEG-SOD groups significantly different compared to hyperglycemia and hyperglycemia + denatured
PEG-SOD groups).

analysis). We found that the protective effect of PEG-SOD
on force generation in single fibers was observed in all
diaphragm fiber types (Figure 5). However, there were no
fiber type specific differences in pCa50 values (calcium
sensitivity) or N values (Hill coefficient) between control, HG, HG + PEG-SOD and HG + dnPEG-SOD groups.
Hyperglycemia significantly decreased Type IIA fiber cross
sectional area, which was not restored by administration
of PEG-SOD.

Contractile protein levels and indices of protein oxidation

There are several mechanisms by which pathological
stresses can alter contractile protein function. One possible mechanism is via activation of proteolytic pathways
with resultant cleavage and loss of specific contractile
elements. A second process is via chemical modification of

contractile elements through kinase-mediated phosphorylation reactions or sidegroup modifications by reactive
species (for example, nitrosylation of tyrosine residues
by peroxynitrite or carbonyl formation in response to
reaction with ROS species). Moreover, a number of previous studies have shown that oxidative stress in the
diaphragm is associated with alterations in diaphragm
contractile performance [26,38,39].
To determine if hyperglycemia altered the level of
contractile proteins, we measured levels of four proteins
known to play key functions in contractile force generation, including actin, actinin, tropomyosin and troponin
T (Figure 6). We found that hyperglycemia did not result
in depletion of either actin, actinin or tropomyosin but
significantly reduced levels of troponin T, one of the key
proteins involved in the regulation of crossbridge cycling.
We also found that PEG-SOD attenuated this selective
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100
80
60
40
20
0
6.5

6.0
5.5
5.0
2+
pCa (-log[Ca ])

Figure 4 PEG-SOD restores hyperglycemia-induced reductions in diaphragm permeabilized single fiber contractile force generation.
Force pCa relationships in single permeabilized diaphragm fibers from control (black), hyperglycemia (red), hyperglycemia + PEG-SOD (blue), and
hyperglycemia + denatured (heat inactivated) PEG-SOD groups (green) were evaluated at two weeks after administration of citrate buffer (controls) or
streptozotocin (hyperglycemia) (n = 6 animals/group). A total of 15 fibers from each animal were assessed (90 fibers/experimental group, total 360
fibers). As shown, PEG-SOD substantially improved the force-pCa relationship in single permeabilized diaphragm fibers from hyperglycemic animals,
whereas denatured PEG-SOD had no effect to restore single fiber force generating capacity (P < 0.001). PEG-SOD did not normalize glucose
levels. These data suggest that inhibition of superoxide generation in the hyperglycemic diaphragm restores contractile protein function.
PEG-SOD, polyethylene glycol superoxide dismutase.

loss of troponin T, restoring levels to near control values
(P = 0.001 for comparison of all groups).
We also assessed if hyperglycemia induced protein
modifications in the diaphragm known to be associated
with oxidative stress (that is, nitrotyrosine and protein
carbonyl formation). As shown in Figure 7, hyperglycemia induced large increases in diaphragm proteins with
nitrosylated side groups, including a protein migrating
with a molecular weight characteristic of myosin (Band 1).
In addition, hyperglycemia significantly increased diaphragm protein carbonyl side group content (Figure 8)
(P <0.001), with large increases in the carbonyl content
of nine protein bands. Administration of PEG-SOD
largely ablated all hyperglycemia -induced increases in
nitrotyrosine and protein carbonyl side group formation, suggesting that these increases are produced by
ROS-mediated mechanisms. Administration of inactive,
denatured PEG-SOD did not prevent hyperglycemia-

induced increases in either diaphragm nitrotyrosine or
protein carbonyl content.

Discussion
While a limited number of studies have examined the
effects of hyperglycemia on the diaphragm, the majority
of these reports have assessed changes in diaphragm
force generation at much longer durations of hyperglycemia (four to eight weeks) compared to the current
study, with some studies reporting increases in diaphragm
specific force, while others report decreases [40,41]. However, neither of these studies investigated the role of ROS
in the diaphragm alterations they observed. We are aware
of only one previous study that assessed diaphragm specific force generation after two weeks of hyperglycemia,
reporting reductions in diaphragm specific force generation similar to those that we observed and suggesting
a possible link between ROS mediated processes and
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Figure 5 Hyperglycemia reduces single fiber contractile force generation in all fiber types. Fiber typing was performed for each diaphragm
fiber in which force-pCa relationships were determined and then evaluated to assess if the changes in force were related to a specific fiber type. A total
of 346 fibers were typed and subsequently classified as Type I (slow), Type IIA, Type II B, Type IIX, Type IIB/X and mixed based on the migration pattern
of myosin heavy chains (determinations were not made for 14 fibers due to technical issues). A) depicts a representative gel for determination of
individual fiber type. The first lane is a protein standard obtained from total diaphragm homogenates which contains all myosin heavy chain
isoforms, the other lanes indicate myosin heavy chain isoforms from individual fibers. The image was obtained from the same gel, but lanes
were not adjacent and are demarcated by the lines within the representative image. B) represents the effect of fiber type on maximal single
fiber contractile force generation in response to hyperglycemia, hyperglycemia + PEG-SOD and hyperglycemia + denatured (heat inactivated)
PEG-SOD. The absolute force generation/CSA in kPa is indicated for the different fiber types from the four experimental groups. As shown,
hyperglycemia reduced single fiber contractile force generation in all diaphragm fiber types. Administration of PEG-SOD, but not denatured
PEG-SOD, largely restored contractile force generation in single permeabilized diaphragm fibers independent of fiber type (P < 0.001, * significantly
different when compared to control and hyperglycemia + PEG-SOD fibers). PEG-SOD, polyethylene glycol superoxide dismutase.

reductions in diaphragm contractility [27]. However,
this study did not examine intracellular targets of
hyperglycemia-induced changes in the diaphragm, did
not examine single diaphragm fiber force generation,
did not assess contractile protein content and did not
measure any indices of diaphragm oxidative stress in
response to hyperglycemia.
In contrast to this previous work, we found that hyperglycemia induced reductions in diaphragm contractility
occur largely at the level of the contractile proteins with
resultant loss of diaphragm troponin T and increased indices of oxidative stress. Moreover, the present work is the
first to show that administration of a selective superoxide
scavenger, PEG-SOD, completely reversed hyperglycemia-

induced diaphragm weakness, increasing force generation
in response to the entire range of physiologically relevant
stimulation frequencies. In addition, by using single permeabilized fiber techniques, we demonstrate that the
contractile proteins are a major intracellular target of
hyperglycemia with hyperglycemia inducing both a reduction in maximum contractile protein force generation
and a reduction in thin filament interactions. We also
show that administration of PEG-SOD reverses hyperglycemia -induced alterations in contractile protein function, improving maximum force generating capacity and
restoring thin filament cooperativity, providing evidence
that this process is, in part, mediated by free radical generation and, specifically, by excessive superoxide generation.
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Figure 6 Hyperglycemia induces selective depletion of diaphragm troponin T. Representative western blots and mean densitometry of key
contractile proteins from diaphragm homogenates from control (black), hyperglycemic (red), hyperglycemic + PEG-SOD (blue), and hyperglycemic +
denatured (heat inactivated) PEG-SOD groups (n = 6 for each comparison). Images were obtained from the same gel, but lanes were not adjacent and
are demarcated by the lines within the representative image. Actin levels are shown in A), actinin levels in B), tropomyosin levels in C) and troponin T
levels in D). Blots were reprobed with tubulin as a loading control. Densitometry is presented in arbitrary units and was normalized to control values.
There were no significant differences in the protein contents of actin, actinin, or tropomyosin between groups. On the other hand, troponin T levels
were significantly decreased with hyperglycemia; this loss of troponin T was prevented with administration of PEG-SOD, but not with denatured
PEG-SOD (P <0.001). These data demonstrate that a superoxide scavenger preserves hyperglycemia -induced loss of troponin T in the diaphragm.
(* significantly different from control and hyperglycemic + PEG-SOD groups). PEG-SOD, polyethylene glycol superoxide dismutase.

It is known that hyperglycemia increases free radical
generation in tissues other than skeletal muscle [17,18,42].
More importantly, this previous work also indicates
that excessive generation of superoxide and other ROS
(for example, peroxynitrite, hydrogen peroxide) plays an

important role in the genesis of hyperglycemia-induced
tissue damage in several organs [17,18,43,44]. For example,
hyperglycemia-induced endothelial dysfunction is thought
to be linked to excessive glucose entry into endothelial cells
leading to an increase in NADH production within the
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Figure 7 Hyperglycemia increases tyrosine nitration of several diaphragm proteins. A) is a representative blot for nitrotyrosine staining in
diaphragm homogenates from control (black), hyperglycemic (red), hyperglycemic + PEG-SOD (blue), and hyperglycemic + denatured (heat inactivated)
PEG-SOD animals. B) indicates mean ± SEM of the densitometric analyses for Bands 1 to 4 (n = 6 for comparisons between the four experimental groups).
As shown, at least four band differences were noted between control and hyperglycemic diaphragm homogenates; administration of PEG-SOD to
hyperglycemic animals largely reversed the hyperglycemia-induced changes in nitrotyrosine staining in diaphragm homogenates, suggesting
that the PEG-SOD-induced reductions in superoxide generation prevented peroxynitrite formation and subsequent tyrosine nitration of proteins.
These effects were not seen with administration of denatured PEG-SOD. (P <0.001, *significantly different when compared to control or
hyperglycemia + PEG-SOD). PEG-SOD, polyethylene glycol superoxide dismutase; SEM, standard error of the mean.

mitochondria, enhanced reduction of the proximal portion of the electron transport chain and resultant increases
in electron transport chain superoxide generation [45,46].
Inhibition of this mechanism of superoxide generation
has been shown to prevent hyperglycemia-induced endothelial dysfunction in animal models [32]. Similarly,
hyperglycemia-induced retinal damage has been linked
to retinal superoxide generation by NADPH oxidase,
with reports indicating that administration of superoxide scavengers prevents diabetes-induced retinal damage [17,18]. The present study extends this previous work,
indicating that a superoxide scavenger can also prevent
hyperglycemia-induced diaphragm weakness. We did not

identify the source of excessive diaphragm ROS generation in response to hyperglycemia in the present study,
but these previous studies as well as studies examining
ROS production in skeletal muscle, suggest a number
of potential sites including the mitochondrial electron
transport chain, NADPH oxidase, xanthine oxidase and
uncoupled nitric oxide synthase [47,48]. While mitochondria are implicated as the most important source
of superoxide in skeletal muscle, a recent study suggests
that NADPH oxidase is the major source of superoxide
generation in skeletal muscle at rest and during contraction [49]. Ongoing studies in our lab are designed to
elucidate which of these sources of superoxide generation
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Figure 8 Hyperglycemia increases protein carbonyl modifications in the diaphragm. A) is a representative oxyblot in diaphragm
homogenates from the four experimental groups. Image was obtained from the same gel, but lanes were not adjacent and are demarcated
by the lines within the representative image. As shown, hyperglycemia produced multiple protein carbonyl modifications of diaphragm proteins. B)
is the mean ± SEM of the total lane densitometry of the four experimental groups (n = 4). Administration of PEG-SOD, but not denatured PED-SOD,
largely abolished these modifications indicating that excessive superoxide generation mediates this process. (P <0.001, *significantly different when
compared to control or hyperglycemia + PEG-SOD). PEG-SOD, polyethylene glycol superoxide dismutase; SEM, standard error of the mean.

are pathogenetically linked to the development of hyperglycemia-induced diaphragm dysfunction.
Our observation that ROS play a role in producing
diaphragm weakness during hyperglycemia is consistent
with several previous reports indicating that excessive
ROS generation mediates the development of diaphragm
dysfunction in a variety of animal models of disease including congestive heart failure, mechanical ventilationinduced inactivity, sepsis, and during fatigue [23,25,50,51].
In these other conditions, as in the present study, there is
evidence of excessive ROS generation in the diaphragm,
protection from force loss when superoxide scavengers
are administered, and superoxide dependent reductions in
parameters of single fiber contractile protein function (for
example, reductions in the Fmax) [24]. Additional data
suggest that there are several mechanisms by which free
radical species alter contractile protein function. First, we
have shown that when various free radical generating
solutions are applied directly to the diaphragm single fiber
contractile proteins, superoxide anions, hydroxyl radicals
and peroxynitrite each depress maximal contractile protein force generation (Fmax) [32,34]. In addition to these
direct effects on contractile proteins, ROS have been
shown to activate a variety of signaling kinases in skeletal muscle including JNK, PKR and p38 [52-54]. These
kinases, in turn, trigger alterations in a variety of downstream pathways in skeletal muscle, including the intrinsic
caspase pathway, the extrinsic caspase pathway, components of the proteasomal degradation pathway and factors
regulating protein translation (for example, eIF2α, SK6)

[29,30,55-62]. In addition, ROS are also known to activate
the calpain proteolytic system in skeletal muscle [58,61].
While the exact effects of activated calpain, the activated
proteasomal system and a sudden reduction in protein
translation on contractile protein function are not known,
activated caspase induces alterations in contractile protein
function that are similar to those observed in response
to hyperglycemia in the present study, that is, caspase
induces large reductions in Fmax and alters N, the index
of thin filament cooperativity [63]. In addition, Smuder
et al. reported that oxidative modification of diaphragm
myofibrillar proteins increases their susceptibility to caspase and calpain mediated degradation [57]. As a result,
the pattern of alterations in contractile protein function
induced by hyperglycemia in the present study is similar
to that seen in response to several known effects of ROS,
that is, the direct effects of ROS on contractile protein
function and the effects of ROS triggered proteolysis on
the contractile proteins. We also found that hyperglycemia
induced a significant reduction in troponin T levels,
with this effect inhibited by PEG-SOD administration.
Troponin T is a target of both activated caspase and activated calpain [64,65], and it is possible that hyperglycemia
induced loss of this particular contractile protein through
ROS mediated activation of these proteolytic enzymes.
Additional work will be needed to determine the exact
role of the various downstream effects of ROS in altering
contractile protein function in hyperglycemia and to
also evaluate the specific mechanisms responsible for
the observed depletion of troponin.
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Limitations

There are several elements of our methodology that
require careful consideration. We chose to use the STZ
model to induce hyperglycemia in our animals. While
this is a well established model of hyperglycemia which
reproducibly produces similar, sustained elevations in blood
glucose levels in animals, a potential criticism is that STZ
per se could have some unrecognized toxicity that may
directly affect muscle function, potentially influencing
our results. To exclude this possibility, we administered
insulin to STZ animals (n = 3) and compared the forcefrequency relationship in insulin-treated STZ animals
to those animals given STZ alone, reasoning that if STZ
per se was responsible for the alterations in diaphragm
function we observed, these abnormalities would not
improve with restoration of euglycemia. We found that
insulin treatment markedly improved diaphragm contractility in STZ-treated animals (see figure in Additional file 3:
Figure S2), indicating that in our model, diaphragm
weakness is not due to a toxic effect of STZ, but rather,
is secondary to the effects of hyperglycemia.
Another potential criticism is that the STZ model does
not completely replicate the hyperglycemia of stress seen
in critically ill patients. Studies have suggested that hyperglycemia in ICU patients primarily arises from increased
insulin resistance rather than loss of insulin secretion [66].
In the present study, we employed a dose of STZ that
was sufficiently low such that complete loss of insulin
secretion would not occur [67,68]. Moreover, at these
doses of STZ, animals gradually develop peripheral insulin
resistance over a period of weeks [69]. As a result, this
model induces a form of hyperglycemia (peripheral resistance to insulin, moderate reductions in insulin levels) that
is a reasonable simulation of what occurs in critically ill
patients. Recently, other investigators have used animal
models of critical illness (trauma, hemorrhage, sepsis,
burn injury) in combination with glucose loading to
mimic stress induced hyperglycemia [70-72]. However,
use of such complex models would make it difficult to
discriminate between the effects of the underlying injury
from the effects of hyperglycemia on diaphragm function.
Nevertheless, it will be of interest to determine if the
same phenomena observed in the present study are also
observed in some of these other animal models.
Our data provide strong evidence that hyperglycemiainduced superoxide generation mediates diaphragm weakness. However, in the present study, we did not identify
the intracellular source of superoxide. As indicated above,
we are performing additional studies to identify the precise source of superoxide generation in the diaphragm in
response to hyperglycemia. In addition, the fact that we
observed increased nitrotyrosine formation in diaphragm
homogenates suggests that hyperglycemia may also result
in excessive generation of nitric oxide and/or reactive
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nitrogen species, and the role of nitric oxide in the genesis
of hyperglycemia-induced diaphragm weakness warrants
further exploration. Finally, while we provide evidence of
ROS mediated protein modifications in the diaphragm, in
addition to depletion of troponin T, future studies will be
needed to identify further other protein modifications
as well as the proteolytic processes that may account
for hyperglycemia-induced physiologic derangements in
diaphragm contractility. Nonetheless, our findings represent an important first step in characterizing the effects of
hyperglycemia on respiratory muscle function.

Conclusions
Previous work indicates that poor glycemic control in
critically ill patients increases the incidence of ICU
acquired diaphragm weakness and prolongs duration of
mechanical ventilation. The present study provides mechanistic information regarding the effects of hyperglycemia
on diaphragm contractility, and potentially explains how
this specific risk factor might contribute to diaphragm
weakness and impact weaning from mechanical ventilation in critically ill patients. The obvious treatment for
hyperglycemia in critical illness is insulin therapy; however, the data that indicate that this approach prevents
ICU acquired diaphragm weakness show that strict glycemic control with intensive insulin therapy is required.
Moreover, recent studies suggest that this approach
increases ICU mortality, primarily due to complications
arising from hypoglycemia [73-75], and as such, current
clinical recommendations for the management of hyperglycemia in critically ill patients do not support the use of
strict glucose control. Importantly, the data from the
present study show that hyperglycemia-induced respiratory
muscle weakness can be prevented by administration of a
superoxide scavenger (PEG-SOD), as this agent dramatically restored diaphragm function in hyperglycemic animals
despite having no effect on glucose levels. Moreover,
diaphragm weakness improved dramatically even though
treatment with PEG-SOD was delayed for one week after
hyperglycemia was present. Therefore, it seems reasonable to speculate that treatment with agents that target
ROS may provide an alternative approach to prevent
hyperglycemia-induced respiratory muscle dysfunction
in critical illness. Nonetheless, additional clinical studies
will be needed to assess the efficacy of such therapies in
mechanically ventilated hyperglycemic ICU patients.
Key messages
 Hyperglycemia induces diaphragm weakness and is

associated with loss of troponin T and increased
markers of oxidative stress.
 Alterations in diaphragm specific force generation in
response to hyperglycemia occur at the level of the
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contractile proteins and are independent of
diaphragm fiber type.
 Administration of PEG-SOD, a specific scavenger
of superoxide, prevents hyperglycemia-induced
diaphragm weakness, restoring both intact diaphragm
force generation as well as single fiber diaphragm
force generation without lowering glucose levels.
 Our data identify new mechanisms for hyperglycemia
induced diaphragm weakness, and potentially explain
how poor glucose control might potentiate the
development of diaphragm weakness and prolong
the duration of mechanical ventilation during
critical illness.

Additional files
Additional file 1: Figure S1. Final diaphragm weight to final animal
weight ratios. This is a graph demonstrating the final diaphragm weight
to final animal weight ratios in the experimental groups.
Additional file 2: Table S1. Fiber type specific data in single
permeabilized diaphragm fibers from all experimental groups. This is a
table showing the detailed analyses of single fiber experiments based on
fiber type as determined by the myosin heavy chain content in individual
fibers; included are fiber type specific parameters of maximal force
generation per cross sectional area (kPa), cross sectional area, N values
(Hill coefficient) and the pCa50.
Additional file 3: Figure S2. Effect of insulin treatment on diaphragm
specific force generation. This figure demonstrates the effects of insulin
treatment in hyperglycemic animals on the diaphragm specific force
generation.
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